Not finding it? Sign in to also search OpenAlex live.
-
Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy2020 Kidney International Reports article Medicine Renal Diseases and Glomerulopathies Open access cited by 18 patents
Richard A. Lafayette, Brad H. Rovin, Heather N. Reich, James Alan Tumlin, Jürgen Floege, Jonathan Barratt
159citations -
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial
Anna Paula Brandt, Christoph Schultheiß, Konrad Friedrich Klinghammer, Philippe Schafhausen, Chia‐Jung Busch, Markus Blaurock, +8 more
11citations -
ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase
Andreas Hochhaus, Susanne Saußele, François‐Xavier Mahon, Virginia Pilipovic, Yifan Zhang, Peter Schuld, +1 more
1citations -
Tiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial2025 Advances in Therapy article Biochemistry, Genetics and Molecular Biology Protease and Inhibitor Mechanisms Open access
Ingmar Bergs, Stephan Budweiser, Hans‐Heinrich Henneicke‐von Zepelin, Hagen Kelm, Tom Bollmann, Johannes-Josef Tebbe, +6 more
0citations -
Identification and Rating of Treatment Goals in Schizophrenia: Delphi Process and Concordance Survey in Matched Physician-Patient Pairs2025 Patient Preference and Adherence article Medicine Schizophrenia research and treatment Open access
Gerhard Gründer, Philipp Bauknecht, Stefanie Schell, Karolina Leopold, Michael Paulzen, Stefan Leucht
2citations -
Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial2021 Intensive Care Medicine article Medicine Sepsis Diagnosis and Treatment Open access cited by 3 patents
Pierre‐François Laterre, Peter Pickkers, Gernot Marx, Xavier Wittebole, Ferhat Meziani, Thierry Dugernier, +71 more
99citations -
Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
Rahul Raj Aggarwal, Ana Maria Aparicio, Axel Heidenreich, Shahneen Kaur Sandhu, Yiran Zhang, Mark Salvati, +1 more
14citations -
Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE).
Andreas Hochhaus, F.-X. Mahon, Tim H. Brümmendorf, Phillipp D. Le Coutre, David Jacob Andorsky, Susanne Saußele, +14 more
3citations -
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study
Gianantonio Rosti, Tim H. Brümmendorf, Bjørn Tore Gjertsen, Pilar Giraldo-Castellano, Fausto Castagnetti, Carlo B Gambacorti-Passerini, +6 more
10citations -
Tolerability of high dose chemotherapy and autologous stem cell transplantation in elderly patients with multiple myeloma: A single-center retrospective analysis2020 Current Research in Translational Medicine article Medicine Multiple Myeloma Research and Treatments
H. Wiebach, Deniz Gezer, Tim H. Brümmendorf, Martina Margrit Crysandt, Stefan Wilop
7citations -
CML-766: Primary Endpoint Results of the Phase 3b ASC4START Trial of Asciminib vs Nilotinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML-CP): Time to Treatment Discontinuation Due to Adverse Events (TTDAE)2025 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Chronic Myeloid Leukemia Treatments
Stephen Anthony Strickland, Andreas Hochhaus, Susanne Saußele, François Xavier Mahon, Philipp le Coutre, Delphine Réa, +14 more
0citations -
A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, an anti-PSMA radioconjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC).2025 Journal of Clinical Oncology conference-abstract Medicine Prostate Cancer Treatment and Research
Andrei H. Iagaru, GIUSEPPE T. CARDACI, Aaron Richard Hansen, Jeffrey Y.C. Wong, Carlos Artigas, Karolien E. Goffin, +7 more
0citations -
Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study
Tim H. Brümmendorf, Patrick G. Medd, Raphael Koch, Stephan Stilgenbauer, Shringi Sharma, Yun He, +4 more
8citations -
P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL2023 HemaSphere article Biochemistry, Genetics and Molecular Biology RNA Interference and Gene Delivery Open access
Giovanni Marconi, Shukaib Arslan, Shaun A. Fleming, Antonio Curti, James Stewart Blachly, Giovanni Martinelli, +15 more
0citations